HOME >> BIOLOGY >> NEWS
Breast-feeding plays second fiddle to work, study finds

COLUMBUS, Ohio -- Research now shows what a mother already knows -- that the demands of her job have a direct impact on how long and how often she breast-feeds.

Working women make fundamental decisions about breast-feeding based on when they go back to their jobs, said Brian Roe, an assistant professor of agricultural, environmental and development economics at Ohio State University and study co-author.

"There is competition between breast-feeding and employment," he said. "In our study, the women who worked full-time represented the lowest percentage of breast-feeders, while the women working one to nine hours per week breast-fed most frequently."

The research appeared in a recent issue of the journal Demography.

Roe and his colleagues surveyed 712 women who planned to return to work within 12 months of giving birth. Each mother was asked to complete 11 questionnaires at various times throughout late pregnancy until 12 months postpartum. The researchers used data from the surveys to calculate the duration of both breast-feeding and leave from work. They also compared daily work hours and breast-feedings at infant ages three and six months. Breast-feedings also included breast milk expressed from the mother and fed to the infant by a bottle.

About half (54 percent) of the women who returned to full-time wor
'"/>

Contact: Brian Roe
Roe.30@osu.edu
614-688-5777
Ohio State University
26-Oct-1999


Page: 1 2 3

Related biology news :

1. Washington University in St. Louis plays key role in sequencing moss genome
2. Maternal DHA levels plays important role in infant development
3. Gene plays major role in formation of stem cells and cancer
4. Hormone linked to obesity plays positive role in fertility & possibly male arousal
5. Changes in shape of single protein plays key role in the spread of cancer cells
6. Researchers find role RNA plays in progress of Alzheimers disease
7. UT Southwestern researchers pinpoint role cell surface protein group plays in brain function
8. Gene that drives cells to commit suicide also plays key role in development of skeletal muscle
9. Cox-2 enzyme plays important role regulating acute pancreatitis and associated lung injury
10. Field Museum plays key role in massive project to map Tree of Life
11. Genetic mutation plays major role in adrenal cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breast feeding plays second fiddle work study finds

(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: